Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Cartesian Therapeutics (RNAC) and Vertex Pharmaceuticals (VRTX)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Mineralys Therapeutics, Inc. (MLYS – Research Report), Cartesian Therapeutics (RNAC – Research Report) and Vertex Pharmaceuticals (VRTX – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mineralys Therapeutics, Inc. (MLYS)
In a report released today, Annabel Samimy from Stifel Nicolaus maintained a Buy rating on Mineralys Therapeutics, Inc., with a price target of $52.00. The company’s shares closed last Monday at $27.24.
According to TipRanks.com, Samimy is a 5-star analyst with an average return of
Currently, the analyst consensus on Mineralys Therapeutics, Inc. is a Strong Buy with an average price target of $52.00, implying a 93.7% upside from current levels. In a report released today, LifeSci Capital also maintained a Buy rating on the stock with a $54.00 price target.
See the top stocks recommended by analysts >>
Cartesian Therapeutics (RNAC)
Wedbush analyst Martin Fan maintained a Buy rating on Cartesian Therapeutics today and set a price target of $38.00. The company’s shares closed last Monday at $9.02.
According to TipRanks.com, Fan is a 4-star analyst with an average return of
Currently, the analyst consensus on Cartesian Therapeutics is a Strong Buy with an average price target of $34.00, representing a 419.1% upside. In a report released yesterday, Cantor Fitzgerald also upgraded the stock to Buy with a $16.00 price target.
Vertex Pharmaceuticals (VRTX)
In a report released today, Paul Matteis from Stifel Nicolaus maintained a Hold rating on Vertex Pharmaceuticals, with a price target of $466.00. The company’s shares closed last Monday at $460.87.
According to TipRanks.com, Matteis is a 5-star analyst with an average return of
Vertex Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $563.00, a 23.6% upside from current levels. In a report released today, Needham also maintained a Hold rating on the stock with a $460.00 price target.
